Serum Presepsin as Early Predictor for Neonatal Early-onset Sepsis
- Conditions
- Neonatal Sepsis
- Interventions
- Diagnostic Test: Serum Presepsin
- Registration Number
- NCT05022043
- Lead Sponsor
- Tanta University
- Brief Summary
124 neonates aged ≤7 days with suspected EOS were clinically evaluated using SNAP-II and gave blood samples for BC, total leucocytic count (TLC), lymphocytic and neutrophil count, and ELISA estimation of serum levels of PSP, procalcitonin (PCT), and tumor necrosis factor-α (TNF-α). Enrolled neonates were categorized as Confirmed EOS: neonates with evident clinical sepsis manifestations and positive BC, Suspected EOS: neonates with evident clinical sepsis manifestations but had negative BC and No EOS included neonates free of evident clinical sepsis manifestations, had negative BC and showed no deterioration till 72-hr after admission.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 124
- included gestational age (GA) of 28-41 weeks and 5-min APGAR score of ≥7, and neonatal age of <7 days
- including small for gestational age, presence of a chromosomal abnormality, multiple congenital anomalies, genetic syndromes, history of premature rupture of membranes, chorioamnionitis, neonatal asphyxia, and missed inclusion criterion.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description EOS Serum Presepsin -
- Primary Outcome Measures
Name Time Method prediction of neonatal outcome one week Ability of Serum Presepsin to disseminate neonates with confirmed EOS
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Tanta university
🇪🇬Tanta, Egypt